Last reviewed · How we verify
Placebo of IR tablet
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Clinical trial control arm (Phase 3).
At a glance
| Generic name | Placebo of IR tablet |
|---|---|
| Sponsor | Reckitt Benckiser Healthcare (UK) Limited |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish baseline efficacy and safety of an investigational drug. Any observed effects are attributed to the placebo effect (psychological and contextual factors) rather than a specific molecular mechanism. Placebos are essential for blinded study designs to isolate the true therapeutic benefit of the active drug being tested.
Approved indications
- Clinical trial control arm (Phase 3)
Common side effects
Key clinical trials
- A Study of Idazoxan in Healthy Participants (PHASE1)
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency (PHASE3)
- Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression (PHASE2)
- ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) (PHASE2)
- Human Models of Selective Insulin Resistance: Alpelisib, Part I (PHASE1)
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) (PHASE3)
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC (PHASE2)
- ACTIV-6: COVID-19 Study of Repurposed Medications (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of IR tablet CI brief — competitive landscape report
- Placebo of IR tablet updates RSS · CI watch RSS
- Reckitt Benckiser Healthcare (UK) Limited portfolio CI